课题基金 / 基金详情

Structure And Stabilization Of The Bacterial Nucleoid

Structure And Stabilization Of The Bacterial Nucleoid
细菌核的结构和稳定性
批准号:
6664158
负责人:
Steven C. Zimmerman
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Steven C. Zimmerman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The DNA of bacteria is localized in a few compact bodies per cell known as nucleoids. Control of compaction offers a virtually unexplored means of interacting with and potentially controlling bacterial growth. We have previously developed quantitative procedures to assay factors that are involved in nucleoid compaction in Escherichia coli. One of these factors, known for 30 years but never identified, is characterized by its RNase-sensitivity. By use of the new assay procedures, this RNase-sensitive component has been identified as the ribosomal link in cotranslational insertion linkages between the nucleoidal DNA and the cell envelope. The rounded nucleoids ("cm-nucleoids)that are formed upon exposure of E. coli to chloramphenicol, as well as under several other conditions, are of particular interest. Cm-nucleoids are extraordinarily stable to denaturation and appear to be formed by a relatively direct and efficiently reversible conversion from normal nucleoids, offering potential insights into the unknown structure of the normal nucleoid. Although a hollow spherical model had been repeatedly presented for cm-nucleoids by another laboratory, that model is unable to account for the light microscope appearance of a significant fraction of cm-nucleoids. A new type of curved toroidal structure is proposed for cm-nucleoids which can rationalize the previously discordant observations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa
海外基金